3 unknown. 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Unknown 3 |
Follow Jinming Yu: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| WX-0593 Combined With Concurrent Chemoradiotherapy in Unresectable Locally Advanced NSCLC WX-0593 Tablets, chemotherapy, Thoracic Radiation Therapy（TRT） - Non-small Cell Lung Cancer (NSCLC) | Phase 2 | Unknown | Jinming Yu | 40 | 2022-04-30 | 2022-04-28 |
| A Phase Ⅱ Trial of Pyrotinib Combination With CDK4/6 Inhibitor SHR6390 in Patients Prior Trastuzumab-treated Advanced HER2-Positive Breast Cancer Pyrotinib, SHR6390, Letrozole - Metastatic Breast Cancer, HER2-positive Breast Cancer | Phase 2 | Unknown | Jinming Yu | 60 | 2019-09-30 | 2019-09-19 |
| Phase II Study of Erlotinib With Concurrent Radiotherapy in Unresectable NSCLC With Activating Mutation of EGFR in Exon 19 or 21 Erlotinib w Concurrent Radiotherapy, etoposide/cis-platin (EP) w Concurrent Radiotherapy - Non-small Cell Lung Cancer | Phase 2 | Unknown | Jinming Yu | 100 | 2012-12-14 | 2017-02-07 |
Carcinoma, Non-Small-Cell Lung (2) · Breast Neoplasms (1)
Capecitabine (1) · Drug Therapy (1) · Letrozole (1) · pyrotinib (1)
China (3)
Baolin Qu, PhD (1) · Bing Lu, PhD (1) · Chun Han, PhD (1) · Conghua Xie, PhD (1) · Gang Wu, PhD (1) · Guang Li, PhD (1) · Guangying Zhu, PhD (1) · Jiancheng Li, PhD (1) · Jianhua Wang, PhD (1) · Lvhua Wang, PhD (1) · Ming Chen, PhD (1) · Qibin Song, PhD (1) · Qin Lin, PhD (1) · Shenglin Ma, PhD (1)